

Learning Objectives for Last-Chance Ambulatory Care Review Webinar

September 6, 2012

Biostatistics and Hypertension/Dyslipidemia

0217-0000-12-130-L01-P

Biostatistics

Kevin M. Sowinski, Pharm.D., FCCP

Professor of Pharmacy Practice, Purdue University College of Pharmacy

Adjunct Professor of Medicine, Indiana University School of Medicine

Indianapolis, Indiana

By the end of this presentation, participants should be able to:

1. For statistical tests commonly encountered in the pharmacotherapy literature, describe their appropriate application and interpretation.
2. Differentiate observational and controlled trial designs based upon their strengths and weaknesses
3. Detect common hazards in presenting and interpreting the statistical results of various trial types.

Hypertension/Dyslipidemia

Karen J. McConnell, Pharm.D., BCPS

Clinical Pharmacy Specialist, Clinical Pharmacy Cardiac Risk Service (CPCRS)

Clinical Associate Professor, School of Pharmacy

University of Colorado Denver

Aurora, Colorado

By the end of this presentation, participants should be able to:

1. Develop and implement a detailed medication plan for dyslipidemia based on evidence-based and case-specific information.
2. Appropriately monitor and assess the effectiveness of dyslipidemia therapy as recommended by national guidelines.
3. Develop and implement a detailed medication plans for hypertension based on evidence-based and case-specific information.
4. Appropriately monitor and assess the effectiveness of hypertension therapy as recommended by national guidelines.

September 7, 2012

Psychiatric Disorders and Infectious Diseases
0217-0000-12-131-L01-P

Psychiatric Disorders

Carol A. Ott, Pharm.D., BCPP

*Clinical Associate Professor of Pharmacy Practice, College of Pharmacy,
Purdue University;*

*Clinical Pharmacy Specialist in Psychiatry, Wishard Health Services and
Midtown Community Mental Health
Indianapolis, Indiana*

By the end of this presentation, participants should be able to:

1. Recommend appropriate initial and maintenance drug therapy for mood disorders, anxiety disorders, sleep disorders, and schizophrenia.
2. Discuss significant drug interactions and side effects that can affect the pharmacist's recommendations for initial and maintenance therapy for psychiatric disorders.
3. Differentiate the use of psychiatric medications for different disorders, focusing on target doses and expected outcomes for drug therapy.
4. Relate the importance of the therapeutic alliance with the psychiatric patient and provide appropriate patient education regarding drug therapy.

Infectious Diseases

Elizabeth A. Coyle, Pharm.D., BCPS

*Clinical Associate Professor of Infectious Diseases
University of Houston College of Pharmacy;*

Adjunct Assistant Professor

*Department of Infectious Diseases, Infection Control and Employee Health,
and Director of the Infectious Diseases Pharmacy Residency at the University of Texas M.D. Anderson
Cancer Center
Houston, Texas*

By the end of this presentation, participants should be able to:

1. Based on evidence based guidelines, be able to design appropriate treatment regimens, pharmacologic and non-pharmacologic, for various patient populations with urinary tract infections, community-acquired pneumonia, upper respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases.
2. Identify risk factors and clinical circumstances in which antimicrobial resistance is a risk, and be able to appropriately design antimicrobial regimens to treat resistant infections and prevent future development.
3. Apply patient and clinical factors to design antimicrobial regimens that are appropriate, increase compliance and are cost-effective for the patient.